CTNNB1 and desmoid tumor: We are currently using CRISPR/Cas9 mediated gene editing to target CTNNB1 mutagenesis, which will be useful for understanding the mechanisms of different CTNNB1 mutations underlying the development and progression of pediatric desmoid tumors [24].